Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
UBS
Healthtrust
US Army
Citi
Chinese Patent Office
Colorcon
Daiichi Sankyo

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,645,963

« Back to Dashboard

Which drugs does patent 6,645,963 protect, and when does it expire?

Patent 6,645,963 protects ISTALOL and is included in one NDA.

This patent has eight patent family members in seven countries.
Summary for Patent: 6,645,963
Title: Prolonged-action eye drop
Abstract:Eye drops containing a .beta.-blocker such as cartelol hydrochloride are improved in the penetration of the .beta.-blocker into the eye and the retention thereof in the eye tissues by the incorporation of a C.sub.3-7 fatty acid such as sorbic acid to the eye preparations.
Inventor(s): Higashiyama; Masayo (Kobe, JP), Ohtori; Akira (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:09/802,849
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 6,645,963

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bausch And Lomb ISTALOL timolol maleate SOLUTION/DROPS;OPHTHALMIC 021516-001 Jun 4, 2004 AT2 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,645,963

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-302802Nov 05, 1997
Japan10-250009Sep 03, 1998

Non-Orange Book US Patents Family Members for Patent 6,645,963

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,335,335 Prolonged-action eye drop ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
Queensland Health
QuintilesIMS
US Army
Argus Health
Cipla
Johnson and Johnson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.